FAQs on Annovis Bio Inc.'s NYSE Compliance Plan and Its Implications

What is the significance of Annovis Bio receiving an 18-month NYSE compliance window?

This allows Annovis Bio to continue trading on the NYSE while it works to meet the exchange’s minimum market capitalization and stockholders’ equity requirements, ensuring no immediate impact on its operations or SEC reporting obligations.

When does the 18-month compliance window for Annovis Bio begin?

The compliance window begins on March 26, 2025.

What must Annovis Bio do during the 18-month compliance period?

Annovis Bio must meet the milestones outlined in its compliance plan and adhere to all other NYSE listing requirements to continue trading on the exchange.

Does the NYSE compliance notification affect Annovis Bio’s business operations?

No, the notification has no impact on the company’s operations, business activities, or SEC reporting obligations.

What is Annovis Bio’s focus in the pharmaceutical industry?

Annovis Bio is a clinical-stage platform company developing therapies for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, aiming to restore brain function and improve patients’ quality of life.

Where can I find more information about Annovis Bio?

More information is available on the company’s website at www.AnnovisBio.com, and through its social media channels on LinkedIn, X, and YouTube.

How can investors stay updated on Annovis Bio’s latest news?

Investors can access the latest news and updates relating to ANVS in the company’s newsroom at https://ibn.fm/ANVS.

What is InvestorWire’s role in relation to Annovis Bio?

InvestorWire is a specialized communications platform that provides press release syndication and other corporate communications solutions, part of the Dynamic Brand Portfolio that includes Annovis Bio among its clients.